01 julio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Fractional Flow Reserve Calculation From 3-Dimensional Quantitative Coronary Angiography and TIMI Frame Count

Shengxian Tu, PhD∗; Emanuele Barbato, MD, PhD†; Zsolt Köszegi, MD, PhD‡; Junqing Yang, MD§; Zhonghua Sun, MD‖; Niels R. Holm, MD¶; Balázs Tar, MD‡; Yingguang Li, MSc∗; Dan Rusinaru, MD†; William Wijns, MD, PhD†; Johan H.C. Reiber, PhD∗

Objectives: This study sought to present a novel computer model for fast computation of myocardial fractional flow reserve (FFR) and to evaluate it in patients with intermediate coronary stenoses.

01 julio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Outcomes With Post-Dilation Following Transcatheter Aortic Valve Replacement

Rebecca T. Hahn, MD∗; Philippe Pibarot, DVM, PhD†; John Webb, MD‡; Josep Rodes-Cabau, MD†; Howard C. Herrmann, MD§; Mathew Williams, MD∗; Raj Makkar, MD‖; Wilson Y. Szeto, MD§; Michael L. Main, MD¶; Vinod H. Thourani, MD#; E. Murat Tuzcu, MD∗∗; Samir Kapadia, MD∗∗; Jodi Akin, MS††; Thomas McAndrew, MS‡‡; Ke Xu, PhD‡‡; Martin B. Leon, MD∗; Susheel K. Kodali, MD∗

Objectives: This study sought to characterize the patients receiving post-implantation balloon dilation (PD) following transcatheter aortic valve replacement (TAVR) and evaluate procedural outcomes in the PARTNER (Placement of Aortic Transcatheter Valve) I trial.

01 julio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Shared and Differential Factors Influencing Restenosis Following Endovascular Therapy Between TASC (Trans-Atlantic Inter-Society Consensus) II Class A to C and D Lesions in the Femoropopliteal Artery

Osamu Iida, MD∗; Mitsuyoshi Takahara, MD, PhD†; Yoshimitsu Soga, MD‡; Kenji Suzuki, MD§; Keisuke Hirano, MD‖; Daizo Kawasaki, MD¶; Yoshiaki Shintani, MD#; Nobuhiro Suematsu, MD∗∗; Terutoshi Yamaoka, MD††; Shinsuke Nanto, MD, PhD‡‡; Masaaki Uematsu, MD, PhD∗

Objectives: This study sought to investigate factors associated with restenosis after endovascular therapy comparing TASC (Trans-Atlantic Inter-Society Consensus) II classes A to C with class D femoropopliteal (FP) lesions.

01 julio 2014

JACC: CARDIOVASCULAR INTERVENTIONS.

Saibal Kar, MD∗; Dongming Hou, MD, PhD†; Russell Jones‡; Dennis Werner, BS†; Lynne Swanson, DVM†; Brian Tischler, BS†; Kenneth Stein, MD†; Barbara Huibregtse, DVM†; Elena Ladich, MD‡; Robert Kutys, MS‡; Renu Virmani, MD‡

Objectives: This study was designed for conducting a comparative evaluation of the healing response after Watchman (WM) (Boston Scientific, Plymouth, Minnesota) and Amplatzer Cardiac Plug (ACP) (St. Jude Medical, Minneapolis, Minnesota) in a canine left atrial appendage (LAA) model.

01 julio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Operator Radiation Exposure and Physical Discomfort During a Right Versus Left Radial Approach for Coronary Interventions

Herman Kado, MD; Ambar M. Patel, MD; Siva Suryadevara, MD; Martin M. Zenni, MD; Lyndon C. Box, MD; Dominick J. Angiolillo, MD, PhD; Theodore A. Bass, MD; Luis A. Guzman, MD

Objectives: This study sought to assess radiation exposure and operator discomfort when using left radial approach (LRA) versus right radial approach (RRA) for coronary diagnostic and percutaneous interventions.

01 agosto 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Three-Year Outcomes After Revascularization With Everolimus- and Sirolimus-Eluting Stents From the SORT OUT IV Trial

Lisette Okkels Jensen, MD, DMSci, PhD∗; Per Thayssen, MD, DMSci∗; Michael Maeng, MD, PhD†; Evald Høj Christiansen, MD, PhD†; Jan Ravkilde, MD, DMSci‡; Knud Nørregaard Hansen, MD∗; Anne Kaltoft, MD, PhD†; Hans Henrik Tilsted, MD‡; Morten Madsen, MSc§; Jens Flensted Lassen, MD, PhD†

Objectives: The study sought to compare the risk of late outcome with a focus on very late definite stent thrombosis of the everolimus-eluting stent (EES) with that of the sirolimus-eluting stent (SES) at 3-year follow-up.

01 agosto 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients With ST Elevation Myocardial Infarction

Emilio Di Lorenzo, MD, PhD∗; Rosario Sauro, MD∗; Attilio Varricchio, MD, PhD∗; Michele Capasso, MD∗; Tonino Lanzillo, MD∗; Fiore Manganelli, MD∗; Giannignazio Carbone, MD∗; Francesca Lanni, MD∗; Maria Rosaria Pagliuca, MD∗; Giovanni Stanco, MD∗; Giuseppe Rosato, MD∗; Harry Suryapranata, MD, PhD†; Giuseppe De Luca, MD, PhD‡

Objectives: The aim of the current study was to compare everolimus-eluting stents (EES) with sirolimus-eluting stents (SES) in patients undergoing primary angioplasty.

01 julio 2014

JACC. Percutaneous Mitral Valve Repair for Mitral Regurgitation in High-Risk Patients

Donald D. Glower, MD∗; Saibal Kar, MD†; Alfredo Trento, MD†; D. Scott Lim, MD‡; Tanvir Bajwa, MD§; Ramon Quesada, MD¶; Patrick L. Whitlow, MD#; Michael J. Rinaldi, MD∗∗; Paul Grayburn, MD††; Michael J. Mack, MD††; Laura Mauri, MD‡‡; Patrick M. McCarthy, MD‖‖; Ted Feldman

Background: The EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High-Risk registry and REALISM Continued Access Study High-Risk Arm are prospective registries of patients who received the MitraClip device (Abbott Vascular, Santa Clara, California) for mitral regurgitation (MR) in the United States.

01 julio 2014

JACC. Comprehensive Analysis of Mortality Among Patients Undergoing TAVR

Lars G. Svensson, MD, PhD∗; Eugene H. Blackstone, MD∗; Jeevanantham Rajeswaran, PhD∗; Nicholas Brozzi, MD‡; Martin B. Leon, MD†; Craig R. Smith, MD§; Michael Mack, MD‖; D. Craig Miller, MD¶; Jeffrey W. Moses, MD§; E. Murat Tuzcu, MD∗; John G. Webb, MD#; Samir Kapadia, MD∗; Gregory P. Fontana, MD∗∗; Raj R. Makkar, MD∗∗; David L. Brown, MD‖; Peter C. Block, MD††; Robert A. Guyton, MD††; Vinod H. Thourani, MD††; Augusto D. Pichard, MD‡‡; Joseph E. Bavaria, MD§§; Howard C. Herrmann, MD§§; Mathew R. Williams, MD§; Vasilis Babaliaros, MD††; Philippe Généreux, MD§; Jodi J. Akin, MSN‖‖

Background: Patients with severe aortic stenosis (AS) who were deemed too high risk or inoperable for conventional aortic valve replacement (AVR) in the PARTNER (Placement of Aortic Transcatheter Valves) trial were randomized to transcatheter aortic valve replacement (TAVR) versus AVR (PARTNER-A arm) or standard therapy (PARTNER-B arm).

01 julio 2014

JACC. Prognostic Significance of LGE by CMR in Aortic Stenosis Patients Undergoing Valve Replacement

Gilles Barone-Rochette, MD; Sophie Piérard, MD; Christophe De Meester de Ravenstein, MS; Stéphanie Seldrum, MD; Julie Melchior, MD; Frédéric Maes, MD; Anne-Catherine Pouleur, MD, PhD; David Vancraeynest, MD, PhD; Agnes Pasquet, MD, PhD; Jean-Louis Vanoverschelde, MD, PhD; Bernhard L. Gerber, MD, PhD

Background: Prior studies have shown that late gadolinium enhancement (LGE) by cardiac magnetic resonance (CMR) can detect focal fibrosis in aortic stenosis (AS), suggesting that it might predict higher mortality risk.

01 julio 2014

JACC. Predictors of Permanent Pacemaker Implantation in Patients With Severe Aortic Stenosis Undergoing TAVR

George C.M. Siontis, MD∗; Peter Jüni, MD†; Thomas Pilgrim, MD∗; Stefan Stortecky, MD∗; Lutz Büllesfeld, MD∗; Bernhard Meier, MD∗; Peter Wenaweser, MD∗; Stephan Windecker, MD∗

Background: Atrioventricular (AV) conduction disturbances requiring permanent pacemaker (PPM) implantation may complicate transcatheter aortic valve replacement (TAVR). Available evidence on predictors of PPM is sparse and derived from small studies.

01 septiembre 2014

JACC. Impact of Aortic Valve Calcification, as Measured by MDCT, on Survival in Patients With Aortic Stenosis

Marie-Annick Clavel, DVM, PhD∗; Philippe Pibarot, DVM, PhD†; David Messika-Zeitoun, MD, PhD‡; Romain Capoulade, PhD†; Joseph Malouf, MD∗; Shivani Aggarval, MBBS∗; Phillip A. Araoz, MD∗; Hector I. Michelena, MD∗; Caroline Cueff, MD‡; Eric Larose, MD, MSc†; Jordan D. Miller, PhD∗; Alec Vahanian, MD‡; Maurice Enriquez-Sarano, MD∗

Background: Aortic valve calcification (AVC) load measures lesion severity in aortic stenosis (AS) and is useful for diagnostic purposes. Whether AVC predicts survival after diagnosis, independent of clinical and Doppler echocardiographic AS characteristics, has not been studied.

01 septiembre 2014

JACC. Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention

Willem J.M. Dewilde, MD∗; Paul W.A. Janssen, MD†; Freek W.A. Verheugt, MD, PhD‡; Robert F. Storey, MD, PhD§; Tom Adriaenssens, MD, PhD‖; Morten L. Hansen, MD, PhD¶; Morten Lamberts, MD, PhD¶; Jurriën M. ten Berg, MD, PhD†

Abstract: Chronic oral anticoagulant therapy is recommended (class I) in patients with mechanical heart valves and in patients with atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category) score ≥1. When these patients undergo percutaneous coronary intervention with stenting, treatment with aspirin and a P2Y12 receptor inhibitor also becomes indicated. Before 2014, guidelines recommended the use of triple therapy (vitamin K antagonists, aspirin, and clopidogrel) for these patients. However, major bleeding is increasingly recognized as the Achilles’ heel of the triple therapy regimen. Lately, various studies have investigated this topic, including a prospective randomized trial, and the evidence for adding aspirin to the regimen of vitamin K antagonists and clopidogrel seems to be weakened. In this group of patients, the challenge is finding the optimal equilibrium to prevent thromboembolic events, such as stent thrombosis and thromboembolic stroke, without increasing bleeding risk.

01 septiembre 2014

JACC. Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure

George L. Bakris, MD∗; Raymond R. Townsend, MD†; Minglei Liu, PhD‡; Sidney A. Cohen, MD, PhD†; Ralph D’Agostino, PhD§; John M. Flack, MD, MPH‖; David E. Kandzari, MD¶; Barry T. Katzen, MD#; Martin B. Leon, MD∗∗; Laura Mauri, MD, MSc††; Manuela Negoita, MD‡; William W. O’Neill, MD‡‡; Suzanne Oparil, MD§§; Krishna Rocha-Singh, MD‖‖; Deepak L. Bhatt, MD, MPH¶¶

Background: Prior studies of catheter-based renal artery denervation have not systematically performed ambulatory blood pressure monitoring (ABPM) to assess the efficacy of the procedure.

01 septiembre 2014

JACC. Innervation Patterns May Limit Response to Endovascular Renal Denervation

Abraham R. Tzafriri, PhD∗; Felix Mahfoud, MD†; John H. Keating, DVM, DACVP∗; Peter M. Markham, MS∗; Anna Spognardi, BA∗; Gee Wong, BS, HT∗; Kristine Fuimaono, BS‡; Michael Böhm, MD†; Elazer R. Edelman, MD, PhD§

Background: Renal denervation is a new interventional approach to treat hypertension with variable results.